|RxNews Recap for Monday 12-21-09|
|By Mary Davila|
|Monday, 21 December 2009 17:53|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
AlphaRx Inc.'s (OTCBB: ALRX) recently appointed President of China Operations, Ruby Hui, today announced new corporate initiatives and the company's strategic growth plan for China.
The Board of Directors of Bristol-Myers Squibb Company (NYSE: BMY) today declared a 3.2 percent increase in the company’s quarterly dividend, beginning in the first quarter of 2010.
Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, today announced that on December 18, 2009, it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P. (collectively, the “LOF”), and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share.
CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals Inc. announced today that they have merged. This merger brings together the product assets and financial resources of both organizations, including potential Exalgo™ milestone and royalty revenue, CombinatoRx’s portfolio of product candidates and unique drug discovery capabilities.
ICBS Ltd. (OTCPK: ICBT), announced today that it will be targeting U.S. state and municipal regulatory bodies for the sale of the TOGS(TM) 9000 bio-photonic incubation & detection systems.
ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced that treatment with sar9, met(O2)11 Substance P, the active component of Homspera®, revealed a positive adjuvant effect during a preventive study for melanoma vaccine in mice.
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc.(Nasdaq: OGXI) as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA).
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled a conference call for 8:30 a.m. ET on Monday, December 21, 2009.
Levi & Korsinsky is investigating the Board of Directors of Javelin Pharmaceuticals, Inc. (“Javelin” or the “Company”) (AMEX: JAV) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to Myriad Pharmaceuticals Inc. ("Myriad") (NasdaqGM: MYRX).
Merck & Co., Inc. (NYSE: MRK) today announced that Dr. Julie Gerberding has been named president of Merck Vaccines, effective January 25, 2010.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that Dr Roy Eldor will present an overview of the clinical development of Oramed's Oral Insulin capsule.
Through its US-based subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has signed a 3-year marketing, sales and distribution agreement with GenWay Biotech Inc.
S3 Investment Company, Inc. (PINKSHEETS: SIVC) announced that the company has posted the December edition of its shareholder newsletter, which includes a review of the 2009 calendar year and the accomplishments of the company's Redwood Capital subsidiary.
Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12 million for rights to utilize Seattle Genetics’ antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex.
Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) today announced that it has entered into a Loan and Security Agreement with Oxford Finance Corporation ("Oxford") for a $3 million term loan.
Urigen Pharmaceuticals, Inc. (OTCBB:URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101.
Biotechnology company Viral Genetics (Pink Sheets: VRAL) today announced that it filed an updated Information Statement including unaudited consolidated financial statements for the nine months ended September 30, 2009, as well as year-end statements for December 31, 2008 and 2007.
ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced a restructuring of the U.S. co-promotion and ex-U.S. license and collaboration agreements with Bayer Schering Pharma AG and Bayer HealthCare relating to RECOTHROM® Thrombin, topical (Recombinant).